Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia.

Autor: Chintamaneni PK; Department of Pharmaceutics, GITAM School of Pharmacy, GITAM (Deemed to be University), Rudraram, 502329 Telangana, India. Electronic address: pchintam@gitam.edu., Pindiprolu SKSS; Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India. Electronic address: pindiprolusskiran@gmail.com., Swain SS; Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India., Karri VVSR; Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India., Nesamony J; College of Pharmacy and Pharmaceutical Sciences, The University of Toledo HSC, 3000 Arlington Avenue, Toledo, OH, 43614, USA., Chelliah S; College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX-77004, USA., Bhaskaran M; College of Pharmacy and Pharmaceutical Sciences, The University of Toledo HSC, 3000 Arlington Avenue, Toledo, OH, 43614, USA. Electronic address: naren.mahe@gmail.com.
Jazyk: angličtina
Zdroj: Cancer letters [Cancer Lett] 2024 Apr 28; Vol. 588, pp. 216782. Date of Electronic Publication: 2024 Mar 06.
DOI: 10.1016/j.canlet.2024.216782
Abstrakt: Pancreatic cancer poses a significant challenge within the field of oncology due to its aggressive behaviour, limited treatment choices, and unfavourable outlook. With a mere 10% survival rate at the 5-year mark, finding effective interventions becomes even more pressing. The intricate relationship between desmoplasia and hypoxia in the tumor microenvironment further complicates matters by promoting resistance to chemotherapy and impeding treatment efficacy. The dense extracellular matrix and cancer-associated fibroblasts characteristic of desmoplasia create a physical and biochemical barrier that impedes drug penetration and fosters an immunosuppressive milieu. Concurrently, hypoxia nurtures aggressive tumor behaviour and resistance to conventional therapies. a comprehensive exploration of emerging medications and innovative drug delivery approaches. Notably, advancements in nanoparticle-based delivery systems, local drug delivery implants, and oxygen-carrying strategies are highlighted for their potential to enhance drug accessibility and therapeutic outcomes. The integration of these strategies with traditional chemotherapies and targeted agents reveals the potential for synergistic effects that amplify treatment responses. These emerging interventions can mitigate desmoplasia and hypoxia-induced barriers, leading to improved drug delivery, treatment efficacy, and patient outcomes in pancreatic cancer. This review article delves into the dynamic landscape of emerging anticancer medications and innovative drug delivery strategies poised to overcome the challenges imposed by desmoplasia and hypoxia in the treatment of pancreatic cancer.
Competing Interests: Declaration of competing interest The authors of manuscript entitled “Conquering Chemoresistance in Pancreatic Cancer: Exploring Novel Drug Therapies and Delivery Approaches amidst Desmoplasia and Hypoxia” is herewith declaring that there is “No Conflict of Interest” in the above said manuscript.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: